Differentiation of a rib benign lesion from a metastasis using xSPECT Quant

By Mario Jreige, MD; Patrick Omoumi, MD; John O. Prior, MD, PhD; and Marie Nicod Lalonde, MD
Data courtesy of Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

History

A 58-year-old patient with prostatic hypertrophy underwent a prostatectomy, which led to an incidental discovery of adenocarcinoma of the prostate that was staged at T2c N0 M0 with a Gleason score of 7 = 3 + 4.

As part of the initial staging, a 99mTc DPD bone scan was performed on a Symbia Intevo™ 16 SPECT/CT. Three hours following intravenous (IV) administration of 18.9 mCi (700 MBq) of 99mTc DPD, initial planar acquisitions were conducted in the anterior and posterior views. A subsequent SPECT/CT examination using xSPECT Bone™ and xSPECT Quant™ was administered for the thorax.

Although the low intensity of uptake and the solitary nature of the rib lesion is suggestive of a benign origin, the patient’s history of prostate cancer was cause for suspicion. The SPECT/CT and xSPECT Quant findings were reviewed for better characterization of the rib lesion.

1 A posterior planar whole-body image demonstrates a small focal area of slightly increased uptake in the posterior arch of the left ninth rib, which appears suspicious considering the patient’s history of prostate cancer. The intensity of uptake is low and such solitary focal rib lesions are commonly related to trauma or benign conditions.

Data courtesy of Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Clinical Results

2 Posterior projection of the MIP image of xSPECT Bone reconstruction of the thorax shows sharp delineation of focal hot area in the left ninth rib posteriorly. Note the overall sharp margins of the ribs and vertebrae seen with xSPECT Bone.

Data courtesy of Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

3 CT, fused SPECT/CT, and xSPECT Bone images in axial and coronal orientation show focal area of mild hypermetabolism in the posterior arch of left ninth rib (arrows). The CT images show a well circumscribed rib lesion without bony expansion or periosteal thickening.

Data courtesy of Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Clinical Results

Findings

Quantitative SPECT/CT (Figure 4) demonstrated focal uptake in the left ninth rib, with a SUV\textsubscript{max} of 8.02 mg/ml. The results correspond to an intramedullary lesion, without a sign of aggressive growth seen on CT (no cortical rupture or periosteal apposition), most likely of cartilaginous origin.

CT findings of an intramedullary lesion—without cortical erosion or periosteal reaction and thickening—along with the relatively low uptake of \textsuperscript{\textsubscript{99m}}Tc DPD and low SUV observed on xSPECT Quant (< 20 mg/ml),\textsuperscript{1} were suggestive of a benign origin, most likely an enchondroma. Other possibilities included bone dysplasia or the sequelae of a previous bone infarction. Post-operative follow-up showed a non-detectable serum level of prostate-specific antigen (PSA) (< 0.03 ng/ml). The patient maintains a non-detectable PSA level from date to 16 months after surgery (latest follow-up date).

Comments

Solitary rib lesions seen in bone scintigraphy are commonly secondary to trauma or benign pathology, even in patients with known malignancy. However, the intensity of uptake and CT findings within the lesion are vital to the accurate characterization of such lesions. In this patient, the focal lesion in the left ninth rib showed low intensity of uptake and a low SUV\textsubscript{max} of 8.02 with CT findings of a well-circumscribed intramedullary rib lesion without bony expansion, cortical erosion, or periosteal thickening. CT findings—along with low uptake intensity and low SUV\textsubscript{max}, related to a relatively minor level of skeletal hypermetabolism—were all suggestive of a benign origin of the rib lesion, which was deemed an enchondroma. The patient continues to maintain an undetectable level of serum PSA, thus confirming the absence of functioning metastases. xSPECT Quant enabled the estimation of lesion SUV\textsubscript{max}, which was significantly below the usual levels seen in malignant lesions, thus supporting the diagnosis of a benign enchondroma.\textsuperscript{1}

Conclusion

Low SUV\textsubscript{max} in a suspicious focal rib lesion, obtained from xSPECT Quant in combination with CT information, helped in the diagnosis of a benign enchondroma in a patient with known prostate cancer. ●

References

\textsuperscript{1} Threshold based on unpublished institutional research data: Tabotta F, Jreige M, Schaefer N, Prior JO, Nicod-Lalonde M. \textsuperscript{\textsubscript{99m}}Tc DPD bone scan quantification: metastasis of prostate cancer versus osteoarthritis. Oral communication. 30th Annual Congress of the European Association of Nuclear Medicine, Vienna; October 2017.

xSPECT Quant is not commercially available in all countries. Due to regulatory reasons, its future availability cannot be guaranteed. Please contact your local Siemens organization for further details.

The outcomes achieved by the Siemens customers described herein were achieved in the customer’s unique setting. Since there is no “typical” hospital and many variables exist (e.g. hospital size, case mix, level of IT adoption) there can be no guarantee that others will achieve the same results.

Examination protocol

<table>
<thead>
<tr>
<th>Scanner: Symbia Intevo 16</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SPECT</strong></td>
</tr>
<tr>
<td>Injected dose</td>
</tr>
<tr>
<td>Acquisition</td>
</tr>
<tr>
<td><strong>CT</strong></td>
</tr>
<tr>
<td>Tube voltage</td>
</tr>
<tr>
<td>Tube current</td>
</tr>
<tr>
<td>Slice thickness</td>
</tr>
</tbody>
</table>

Data courtesy of Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Legal information: On account of certain regional limitations of sales rights and service availability, we cannot guarantee that all products included in this brochure are available through the Siemens sales organization worldwide. Availability and packaging may vary by country and is subject to change without prior notice. Some/all of the features and products described herein may not be available in the United States.

The information in this document contains general technical descriptions of specifications and options as well as standard and optional features, which do not always have to be present in individual cases.

Siemens reserves the right to modify the design, packaging, specifications, and options described herein without prior notice.

Please contact your local Siemens sales representative for the most current information.

Note: Any technical data contained in this document may vary within defined tolerances. Original images always lose a certain amount of detail when reproduced.

“Siemens Healthineers” is considered a brand name. Its use is not intended to represent the legal entity to which this product is registered. Please contact your local Siemens organization for further details.

Siemens Healthineers Headquarters
Siemens Healthcare GmbH
Henkestr. 127
91052 Erlangen
Germany
+49 9131 84-0
siemens-healthineers.com

Published by
Siemens Medical Solutions USA, Inc.
Molecular Imaging
2501 North Barrington Road
Hoffman Estates, IL 60192
+1 847 304 7700
siemens.com/mi

siemens.com/mi